leadf
logo-loader
viewCyclacel Pharmaceuticals Inc

Cyclacel looking to begin proof of concept study in CLL

CEO Spiro Rombotis from Cyclacel Pharmaceuticals (NASDAQ:CYCC) says the team is planning to initiate a translational clinical study to evaluate their drug CYC065 in combination with venetoclax in chronic lymphocytic leukemia (CLL).

Rombotis says they expect to start enrolling patients in the first half and expects an output of data by the end of 2019. Rombotis says their $26 mln in cash will take them to the end of 2019, enough to hit the company's major milestones.

Quick facts: Cyclacel Pharmaceuticals Inc

Price: 3.92 USD

NASDAQ:CYCC
Market: NASDAQ
Market Cap: $19.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Bragg Gaming showing support for potential new Canadian law allowing Single...

Bragg Gaming Group (CVE: BRAG- OTC: BRGGF) Chief Strategy Officer Yaniv Spielberg joined Steve Darling from Proactive with news the company is very supportive of new legislation put forward by the Canadian Government that, if passed, would allow single-game betting in Canada. Spielberg...

4 hours, 57 minutes ago

2 min read